The results suggest that HLA-E might serve in combination with HLA-G as a prognostic biomarker and its status might contribute to a better selection of a subgroup of RCC patients with poor prognosis, who might benefit from individually tailored (immune) therapies. This evidence concerns the gene HLA-G and renal cell carcinoma.